Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright - InvestingChannel

Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised his price target for Capricor Therapeutics to $12.40 from $3.50 saying the company announced positive results from the pre-specified interim analysis of the Hope-2 trial in patients with Duchenne muscular dystrophy. The stock in midday trading is up 155%, or $4.98, to $8.20. Six-month data showed that CAP-1002 administration in steroid treated boys and young men resulted in statistically significant changes across several independent clinical measures including skeletal, and respiratory muscle functions, Pantginis tells investors in a research note. The analyst views the data “promising” for both primary and secondary endpoints. He reiterates a Buy rating on Capricor Therapeutics.

Related posts

Carl Icahn Increases His Stake In Take-Two Interactive To 10.68%

ValueWalk

iPad Mini Display Outperformed By Kindle Fire HD & Nexus 7

ValueWalk

Foxconn Might Open Manufacturing Plants In The U.S. [REPORT]

ValueWalk

Peter Cundill Protégé Tim McElvaine on Investing in Japan [VIDEO]

ValueWalk

Set Bing Home Page Image As Lock Screen In Windows 8

ValueWalk

Morning Market News: JCP, APO, MCHP, ZIP, ENR, LGF, EA, ATVI, COV, LNT

ValueWalk